Mankind Pharma Intrinsic Value
Mankind Pharma (MANKIND) median intrinsic value is ₹4912.00 from 10 valuation models (range ₹737–₹6140), vs current price ₹2456.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse MANKIND shareholder distribution to track promoter, FII and institutional holdings.
MANKIND Valuation Methods Summary — DCF, Graham Number & P/E
Mankind Pharma intrinsic value across 10 models vs current price ₹2456.00 — upside/downside and value range per method. Read MANKIND ex-dividend dates for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1182.72 | ₹946.18 - ₹1419.26 | -51.8% | EPS: ₹53.76, Sector P/E: 22x |
| Book Value Method | asset | ₹6140.00 | ₹5526.00 - ₹6754.00 | +150.0% | Book Value/Share: ₹4039.27, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4912.00 | ₹4420.80 - ₹5403.20 | +100.0% | Revenue/Share: ₹3473.17, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4912.00 | ₹4420.80 - ₹5403.20 | +100.0% | EBITDA: ₹4096.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹6140.00 | ₹4912.00 - ₹7368.00 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹736.80 | ₹663.12 - ₹810.48 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹830.59 | ₹747.53 - ₹913.65 | -66.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4912.00 | ₹4420.80 - ₹5403.20 | +100.0% | ROE: 13.5%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹2210.41 | ₹1989.37 - ₹2431.45 | -10.0% | EPS: ₹53.76, BVPS: ₹4039.27 |
| Dividend Yield Method | dividend | ₹736.80 | ₹663.12 - ₹810.48 | -70.0% | DPS: ₹1.00, Target Yield: 2.5% |
MANKIND Intrinsic Value vs Market Price — All Valuation Models
Mankind Pharma fair value range ₹737–₹6140 vs current market price ₹2456.00 across 10 valuation models. For current market price and key ratios, visit Mankind Pharma screener.
MANKIND Intrinsic Value Analysis — Undervalued or Overvalued?
Mankind Pharma median intrinsic value ₹4912.00, current price ₹2456.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of MANKIND?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Mankind Pharma (MANKIND) is ₹4912.00 (median value). With the current market price of ₹2456.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹736.80 to ₹6140.00, indicating ₹736.80 - ₹6140.00.
Is MANKIND undervalued or overvalued?
Based on our multi-method analysis, Mankind Pharma (MANKIND) appears to be trading below calculated value by approximately 100.0%.
MANKIND Financial Health — Key Ratios vs Industry Benchmarks
Mankind Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.39 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 13.5% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 26.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.51x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MANKIND Cash Flow Quality — Operating & Free Cash Flow
Mankind Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹3,121 Cr | ₹3,031 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹2,413 Cr | ₹-3,899 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹2,152 Cr | ₹1,112 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1,813 Cr | ₹1,287 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹920 Cr | ₹236 Cr | Positive Free Cash Flow | 7/10 |